Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Annals of Oncology

Volumn 31, Issue 7, 2020, Pages 961-964

  Michot, J M ^a   Albiges, L ^b   Chaput, N ^c   Saada, V ^b   Pommeret, F ^b   Griscelli, F ^b   Balleyguier, C ^a   Besse, B ^b   Marabelle, A ^a   Netzer, F ^a   Merad, M ^b   Robert, C ^b   Barlesi, F ^b   Gachot, B ^b   Stoclin, A ^b  

^a Department of Therapeutic Innovation and Early Testing ^*  (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TOCILIZUMAB; AUTOANTIBODY; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CLINICAL ARTICLE; CORONAVIRUS DISEASE 2019; DRUG EFFICACY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; DIAGNOSTIC IMAGING; PANDEMIC; TREATMENT OUTCOME; VIRUS PNEUMONIA;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; MALE; PANDEMICS; PNEUMONIA, VIRAL; RECEPTORS, INTERLEUKIN-6; RESPIRATORY INSUFFICIENCY; TREATMENT OUTCOME;

EID: 85083292393     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1016/j.annonc.2020.03.300     Document Type: Letter

References (10)

1. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:10223 (2020), 497–506.
2. Channappanavar, R., Perlman, S., Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:5 (2017), 529–539.
3. Wong, C.K., Lam, C.W.K., Wu, A.K.L., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136:1 (2004), 95–103.
4. Conti, P., Ronconi, G., Caraffa, A., et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (CoV-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents, 34(1), 2020, 1.
5. Chen, N., Zhou, M., Dong, X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:10223 (2020), 507–513.
6. Xu, Z., Shi, L., Wang, Y., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:4 (2020), 420–422.
7. Tanaka, T., Narazaki, M., Ogata, A., Kishimoto, T., A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 26:1 (2014), 88–96.
8. Gabay, C., Emery, P., van Vollenhoven, R., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:9877 (2013), 1541–1550.
9. Lee, D.W., Gardner, R., Porter, D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:2 (2014), 188–195.
10. Cao, B., Wang, Y., Wen, D., et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:19 (2020), 1787–1799.